Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Teva Pharmaceutical Industries ADR
(NY:
TEVA
)
17.86
-0.02 (-0.14%)
Streaming Delayed Price
Updated: 12:38 PM EDT, Sep 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Teva Pharmaceutical Industries ADR
< Previous
1
2
3
4
5
6
7
Next >
Teva Reaches Agreement With Florida to Settle the State’s Opioid-Related Claims
March 30, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reaches Agreement With Rhode Island to Settle Opioid-Related Claims
March 21, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reports Fourth Quarter and Full Year 2021 Financial Results
February 09, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
February 24, 2022
Palm Beach, FL –– February 24, 2022 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept...
Via
FinancialNewsMedia
Exposures
COVID-19
Teva Reaches Agreement With Texas to Settle the State’s Opioid-Related Claims
February 07, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Research Finds COVID Pandemic Worsened Health Equity Gap
February 01, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and 2022 Financial Guidance at 8 a.m. ET on February 9, 2022
January 18, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Statement Following New York Jury Ruling in Opioids Trial
December 30, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Launch of First-to-Market Generic Version of Narcan® (Naloxone Hydrochloride Nasal Spray), in the U.S.
December 22, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the U.S.
December 01, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and Election of Early Settlement
November 10, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
The $11 Trillion Healthcare Industry Is About To Change Forever
November 04, 2021
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 4, 2021 – The $11-trillion healthcare industry is going fully digital, disrupting industry giants & government...
Via
FinancialNewsMedia
Teva Becomes First Pharmaceutical Company to Execute Sustainability-linked Bond Tied to both Climate and Access to Medicine Targets
November 03, 2021
From
Teva Pharmaceutical Industries Ltd.
Via
Business Wire
Teva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,000,000,000 of Sustainability-Linked Senior Notes
November 02, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
California Judge Rules That Teva Did Not Cause a Public Nuisance or Make False or Misleading Statements About Opioids
November 01, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
New Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Time to Impending Relapse Compared to Placebo in Patients with Schizophrenia
October 30, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024
October 27, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior Notes
October 27, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reports Third Quarter 2021 Financial Results
October 27, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate
October 26, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021
October 21, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Is This The Most Exciting Medical Breakthrough Of The Decade
October 19, 2021
FN Media Group Presents Oilprice.com Market Commentary London – October 19, 2021 – According to Google’s Health boss David Feinberg… over one billion people a day search Google for health concerns....
Via
FinancialNewsMedia
Teva to Host Conference Call to Discuss Third Quarter 2021 Financial Results at 8 a.m. ET on October 27, 2021
October 01, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva to Present 8 Abstracts on AJOVY® (fremanezumab-vfrm) Injection and Hold Symposium on Healthcare Disparities at WCN
September 30, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Enlists Sarah Michelle Gellar to Launch “Inhaler Tales” Campaign to Raise Awareness About Inhaler Use in Asthma and COPD
September 30, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Reaches Agreement with Louisiana to Settle the State’s Opioid-Related Claims
September 28, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Late-Breaking Data at the International Headache Society & European Headache Federation Joint Congress 2021 Showed AJOVY® (fremanezumab-vfrm) Injection Reduced More Monthly Migraine Days in a Network Meta-Analysis Study with Atogepant and Rimegepant
September 08, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Showcasing Teva’s Commitment to Helping Patients Have More Migraine-Free Days, 18 Abstracts will be presented, Including One Late-Breaker, on AJOVY® (fremanezumab-vfrm) Injection at the International Headache Society and European Headache...
August 30, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Teva Announces Post Hoc Analysis of Long-Term Data Examining Treatment with AUSTEDO® (deutetrabenazine) Tablets in Adult Patients with Tardive Dyskinesia
August 20, 2021
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.